Advertisement
U.S. markets close in 5 hours 55 minutes
  • S&P 500

    5,255.53
    +7.04 (+0.13%)
     
  • Dow 30

    39,781.94
    +21.86 (+0.05%)
     
  • Nasdaq

    16,420.24
    +20.72 (+0.13%)
     
  • Russell 2000

    2,121.64
    +7.29 (+0.34%)
     
  • Crude Oil

    82.38
    +1.03 (+1.27%)
     
  • Gold

    2,223.60
    +10.90 (+0.49%)
     
  • Silver

    24.64
    -0.12 (-0.47%)
     
  • EUR/USD

    1.0813
    -0.0016 (-0.15%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • dólar/libra

    1.2645
    +0.0007 (+0.06%)
     
  • USD/JPY

    151.2780
    +0.0320 (+0.02%)
     
  • Bitcoin USD

    70,927.30
    +1,510.28 (+2.18%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,963.08
    +31.10 (+0.39%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Achillion Pharmaceuticals ACHN- 2019 Top Picks' Mid-Year Update

Bill Mathews, founder and contributing editor to The Cheap Investor, selected Achillian Pharmaceuticals (ACHN) as a more speculative idea for 2019. The stock has risen 69%. Here's his latest update on this biotech firm.

Achillion Pharmaceuticals has been a great investment. It is a clinical-stage biopharmaceutical company focused on advancing its oral small molecule complement inhibitors into late-stage development and commercialization.

Research has shown that an overactive complement system plays a critical role in multiple disease conditions including the therapeutic areas of nephrology, hematology, ophthalmology and neurology.

The company is initially focusing its drug development activities on complement-mediated diseases where there are no approved therapies or where existing therapies are inadequate for patients.

I continue to like Achillion because they have several products in FDA Trials. Their pipeline includes four products in late stage II and two products in stage I. They have a huge amount of cash $254 million.

Currently, 133 institutions own 80% of the float and the top nine institutions purchased 13.5 million more shares than they sold for the quarter ended March 30. Even though I think the stock has the potential of going higher, investors should protect their profits with stop loses.

More From MoneyShow.com:

Advertisement